China’s Tasly to list biotech arm in $1 billion Hong Kong IPO: sources

HONG KONG (Reuters) – China’s Tasly Pharmaceutical Group is planning to list its biopharma unit in Hong Kong to raise about $1 billion, in what is likely to be the largest biotech float in the city this year, people with knowledge of the matter said.
( read original story …)


Related Post

No separate sections on Hong Kong for new history ...
views 9
A new curriculum framework for teaching Chinese hi...
Chinese smartphone giant Xiaomi’s Hong Kong ...
views 13
Xiaomi, the world’s fourth-largest smartphone make...
Hong Kong shares down amid N.Korea, trade tensions
views 13
The top gainers among H-shares were CSPC Pharmaceu...
What Next for BOC HONG KONG HOLDINGS LTD. ORDINARY...
views 13
The stock of BOC HONG KONG HOLDINGS LTD. ORDINARY ...
Why Fook Lam Moon is still Hong Kong’s ‘tyco...
views 16
For more than half a century, Hong Kong has been a...
Flight Review: Hong Kong Airlines’ Impressive A350...
views 16
Hong Kong is a dazzling city. With a dazzling inte...
Hong Kong Dollar Jumps Most in a Month on Corporat...
views 15
The Hong Kong dollar rallied the most in a month a...
Bus driver unionists warn of escalating action as ...
views 17
Bus driver unions in Hong Kong say they would “not...
Greater Bay Area leader calls on Guangdong provinc...
views 15
Han’s trip – his first since he took up the vice-p...
A Payments Battle Is Brewing in Hong Kong
views 24
Alipay’s azure blue logos began appearing two year...